BACKGROUND AND PURPOSE: Virchow-Robin spaces (VRs) are perivascular spaces surrounding the deep perforating brain arteries. VRs dilatation is pathologic, and it could be a manifestation of cerebral small vessel disease. In the present study we assessed the relation between VRs and silent ischemic lesions in a cohort of patients with cerebral small vessel disease. METHODS: We divided dilated VRs on MRI (1.5 Tesla) into three semi-quantitative categories in 165 first ever lacunar stroke patients. We counted asymptomatic lacunar infarcts and graded white matter lesions, and compared the prevalence of vascular risk factors in different categories of VRs. We also determined independent predictors of silent ischemic lesions. RESULTS: VRs at basal ganglia level related to age, hypertension, asymptomatic lacunar infarcts, and white matter lesions. VRs at basal ganglia level predicted silent ischemic lesions (odds ratio 10.58 per higher VRs category; 95 %- confidence interval 3.40 - 32.92). CONCLUSION: Dilated VRs in the basal ganglia relate to the severity of cerebral small vessel disease and might be a manifestation of the same small vessel abnormality that causes silent ischemic lesions. This adds a role for VRs as a potential marker for small vessel disease.
BACKGROUND AND PURPOSE: Virchow-Robin spaces (VRs) are perivascular spaces surrounding the deep perforating brain arteries. VRs dilatation is pathologic, and it could be a manifestation of cerebral small vessel disease. In the present study we assessed the relation between VRs and silent ischemic lesions in a cohort of patients with cerebral small vessel disease. METHODS: We divided dilated VRs on MRI (1.5 Tesla) into three semi-quantitative categories in 165 first ever lacunar strokepatients. We counted asymptomatic lacunar infarcts and graded white matter lesions, and compared the prevalence of vascular risk factors in different categories of VRs. We also determined independent predictors of silent ischemic lesions. RESULTS: VRs at basal ganglia level related to age, hypertension, asymptomatic lacunar infarcts, and white matter lesions. VRs at basal ganglia level predicted silent ischemic lesions (odds ratio 10.58 per higher VRs category; 95 %- confidence interval 3.40 - 32.92). CONCLUSION: Dilated VRs in the basal ganglia relate to the severity of cerebral small vessel disease and might be a manifestation of the same small vessel abnormality that causes silent ischemic lesions. This adds a role for VRs as a potential marker for small vessel disease.
Authors: Tufail F Patankar; Dipayan Mitra; Anoop Varma; Julie Snowden; David Neary; Alan Jackson Journal: AJNR Am J Neuroradiol Date: 2005 Jun-Jul Impact factor: 3.825
Authors: A M J Maclullich; J M Wardlaw; K J Ferguson; J M Starr; J R Seckl; I J Deary Journal: J Neurol Neurosurg Psychiatry Date: 2004-11 Impact factor: 10.154
Authors: Stewart C Ferguson; Annette Blane; Petros Perros; Rory J McCrimmon; Jonathan J K Best; Joanna Wardlaw; Ian J Deary; Brian M Frier Journal: Diabetes Date: 2003-01 Impact factor: 9.461
Authors: D C Bezerra; A R Sharrett; K Matsushita; R F Gottesman; D Shibata; T H Mosley; J Coresh; M Szklo; M S Carvalho; E Selvin Journal: Neurology Date: 2011-12-14 Impact factor: 9.910
Authors: Kejia Cai; Rongwen Tain; Sandhitsu Das; Frederick C Damen; Yi Sui; Tibor Valyi-Nagy; Mark A Elliott; Xiaohong J Zhou Journal: J Neurosci Methods Date: 2015-09-08 Impact factor: 2.390
Authors: Jie Ding; Sigurður Sigurðsson; Pálmi V Jónsson; Gudny Eiriksdottir; Andreas Charidimou; Oscar L Lopez; Mark A van Buchem; Vilmundur Guðnason; Lenore J Launer Journal: JAMA Neurol Date: 2017-09-01 Impact factor: 18.302
Authors: Andreas Charidimou; Zane Jaunmuktane; Jean-Claude Baron; Matthew Burnell; Pascale Varlet; Andre Peeters; John Xuereb; Rolf Jäger; Sebastian Brandner; David J Werring Journal: Neurology Date: 2013-11-27 Impact factor: 9.910
Authors: Rosalind Brown; Helene Benveniste; Sandra E Black; Serge Charpak; Martin Dichgans; Anne Joutel; Maiken Nedergaard; Kenneth J Smith; Berislav V Zlokovic; Joanna M Wardlaw Journal: Cardiovasc Res Date: 2018-09-01 Impact factor: 10.787